AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited
consolidated financial results for the first quarter ended
March 31, 2020. The company reported total revenues for the
first quarter of 2020 of $68.7 million, including revenue of $44.4
million from Feraheme and revenue of $21.8 million from Makena®
(hydroxyprogesterone caproate injection), as well as expense
reductions across the business. The company also reported an
operating loss of $19.6 million and an adjusted EBITDA loss of $5.5
million in the first quarter of 2020.1
Despite strong first quarter results, AMAG’s products are being
impacted by the COVID-19 pandemic as patient visits have declined
during this period. Given the planned divestiture of Intrarosa®
(prasterone) and Vyleesi® (bremelanotide injection) and the impact
of COVID-19, AMAG has implemented a company-wide restructuring,
which will reduce the workforce by approximately 30 percent. AMAG
is withdrawing its 2020 financial guidance due to the uncertainty
surrounding the duration of the COVID-19 pandemic.
“We are sharpening our focus on our priorities of maximizing
Feraheme’s value, retaining patient access to Makena and continuing
to efficiently develop innovative therapies, namely ciraparantag,”
said Scott Myers, AMAG’s president and chief executive officer. “As
we look to the future, it is difficult to estimate the severity and
duration of the COVID-19 pandemic. We’ve seen signs of
stabilization and remain confident in the underlying demand for our
products; however, we cannot speculate on the subsequent speed of
recovery and the overall impact on our business.”
“Based upon the extraordinary dynamics across the industry due
to the COVID-19 pandemic, we have decided to withdraw our 2020
financial guidance,” said Ted Myles, AMAG’s chief financial officer
and chief operating officer. “We remain committed to our previously
stated goal of reducing total operating expenses by more than $100
million in 2020, as compared to 2019, and we are on track to
achieve this objective. Furthermore, we continue to strive towards
returning to profitability this year. The work force reduction that
we announced today is an important step towards achieving these
corporate objectives. While it was a difficult decision, we believe
the organization is now the right size to support our long-term
goals. We’d like to thank our colleagues who are leaving AMAG for
their many contributions to our organization.”
OTHER KEY UPDATES Leadership
Transition: AMAG announced in April that its Board of
Directors appointed Scott Myers as AMAG’s president and chief
executive officer, and a member of the Board, effective
immediately. Mr. Myers is a proven executive who brings nearly
three decades of global pharmaceutical and medical technology
experience to AMAG. Mr. Myers succeeds William Heiden who stepped
down upon Mr. Myers’ appointment.
Supply Chain: At this time, all of the
company’s products remain available and the supply chain has not
been materially affected by COVID-19. AMAG continues to closely
monitor suppliers and supply levels. The company has risk
mitigation plans in place to minimize potential supply
interruptions, including redundant drug substance manufacturing and
inventory safety stock, and will continue to work diligently with
its suppliers to maintain continuous supply as the COVID-19
situation continues to evolve.
Regulatory: In response to the company's
request to the FDA for a meeting to discuss the future of Makena,
the FDA indicated that it was premature to meet at this time as it
was still reviewing the matter. AMAG remains committed to working
collaboratively with the FDA to maintain access to Makena for
eligible pregnant women.
Clinical Trials: The COVID-19 pandemic is an
evolving situation and is having a serious impact on clinical
trials globally. The AMAG-423 Phase 2b/3a clinical trial is a
hospital-based trial and all sites have paused new patient
enrollment. The company has had to pause initiation of new sites
due to the pandemic, significantly impacting recruitment and
enrollment. AMAG continues to work with the FDA to initiate the
ciraparantag Phase 2b trial in healthy volunteers in the U.S.
However, the COVID-19 pandemic has forced the clinical trial sites
where the company expected to conduct the trial to close.
FIRST QUARTER ENDED MARCH
31RevenueFirst quarter revenue totaled
$68.7 million, compared to $75.8 million for the same period in
2019. This decrease was primarily due to a decrease in sales of
Makena stemming from the unfavorable FDA Advisory Committee
recommendation for Makena in October 2019. These decreases were
partially offset by an increase in sales of Feraheme.
- Feraheme achieved first quarter revenue of $44.4 million, an
increase of 11 percent over the same period last year. Feraheme’s
average quarterly market share was 17.2 percent in the first
quarter of 2020, compared to 16.2 percent in the first quarter of
2019.
- Makena first quarter revenue totaled $21.8 million, compared to
$31.3 million in the first quarter of last year.
- Intrarosa revenue in the first quarter of 2020 totaled $3.2
million, compared to $4.4 million in the same period last
year.
($M) |
Three Months Ended March 31, |
|
2020 |
2019 |
Total revenues |
$68.7 |
|
$75.8 |
|
Feraheme |
|
44.4 |
|
|
40.0 |
|
Makena |
|
21.8 |
|
|
31.3 |
|
Intrarosa |
|
3.2 |
|
|
4.4 |
|
Other |
|
(0.7 |
) |
|
0.1 |
|
Operating ExpensesTotal costs and expenses
decreased by $105.3 million to $88.2 million in the first
quarter of 2020, as compared to the first quarter of 2019. In the
first quarter of last year, the company recorded $74.9 million of
acquired in-process research and development (IPR&D) expense in
connection with the acquisition of Perosphere Pharmaceuticals for
the development asset, ciraparantag. Also recorded in the first
quarter of last year was a one-time restructuring charge of $7.4
million related to combining the company's maternal health and
women's health sales forces in February 2019.
- Cost of products sales in the first quarter of 2020 increased
by $5.9 million, as compared with the first quarter of last year,
driven by an increase in amortization expense associated with the
Makena, Intrarosa and Vyleesi intangible assets.
- Research and development (R&D) expenses totaled $11.2
million, compared to $18.1 million in the first quarter of last
year. This decrease was primarily related to lower costs for
Vyleesi following its FDA approval in June 2019.
- Selling, general and administrative (SG&A) expenses
decreased by approximately $22.0 million, or 29 percent, in the
first quarter of 2020, compared to the same period in 2019.
($M) |
Three Months Ended March 31, |
|
2020 |
2019 |
Amortization of intangible assets |
|
$9.8 |
|
|
$3.9 |
|
Direct cost of product sales |
|
14.5 |
|
|
14.5 |
|
Total cost of product
sales |
|
24.3 |
|
|
18.4 |
|
Research and
development expenses |
|
11.2 |
|
|
18.1 |
|
Acquired in-process
research and development |
|
— |
|
|
74.9 |
|
Selling, general and
administrative expenses |
|
52.7 |
|
|
74.7 |
|
Restructuring
expenses |
|
— |
|
|
7.4 |
|
Total costs and expenses |
|
$88.2 |
|
|
$193.5 |
|
Balance Sheet
- As of March 31, 2020, the company’s cash and investments
totaled $124.7 million.
- Long-term debt totaled $320.0 million (representing the
principal amounts outstanding of the 2022 convertible notes).
Operating Loss and Adjusted EBITDA
- The company reported an operating loss of $19.6 million in the
first quarter of 2020, compared to an operating loss of $117.7
million in the same period last year.
- The company reported a loss in adjusted EBITDA of $5.5
million in the first quarter of 2020, compared to a loss in
adjusted EBITDA of $26.6 million in the same period last year.
($M) |
Three Months Ended March 31, |
|
2020 |
2019 |
Operating loss |
|
$(19.6 |
) |
|
$(117.7 |
) |
Non-GAAP adjusted EBITDA1 |
|
$(5.5 |
) |
|
$(26.6 |
) |
1 See reconciliations of GAAP to non-GAAP adjustments at the
conclusion of this press release.
CONFERENCE CALL AND WEBCAST ACCESSAMAG
Pharmaceuticals, Inc. will host a conference call and webcast today
at 8:00 a.m. ET to discuss the company's first quarter 2020
financial results and recent business updates.
DIAL-IN NUMBERSU.S./Canada Dial-in Number:
(877) 412-6083International Dial-in Number: (702)
495-1202Conference ID: 4948155
Replay Dial-in Number: (855) 859-2056Replay International
Dial-in Number: (404) 537-3406Conference ID: 4948155
A telephone replay will be available from approximately 11:00
a.m. ET on May 11, 2020 through midnight on May 18, 2020.
The webcast with slides will be accessible through the Investors
section of the company’s website at www.amagpharma.com. A replay of
the webcast will be archived on the website for 30 days.
USE OF NON-GAAP FINANCIAL MEASURESAMAG has
presented certain non-GAAP financial measures, including non-GAAP
costs and expenses, non-GAAP adjusted EBITDA (earnings before
income taxes, depreciation and amortization) and non-GAAP diluted
shares outstanding. These non-GAAP financial measures exclude
certain amounts, expenses or income, from the corresponding
financial measures determined in accordance with accounting
principles generally accepted in the U.S. (GAAP). Management
believes this non-GAAP information is useful for investors, taken
in conjunction with AMAG’s GAAP financial statements, because it
provides greater transparency regarding AMAG’s operating
performance. Management uses these measures, among other factors,
to assess and analyze operational results and trends and to make
financial and operational decisions. Non-GAAP information is not
prepared under a comprehensive set of accounting rules and should
only be used to supplement an understanding of AMAG’s operating
results as reported under GAAP, not as a substitute for GAAP. In
addition, these non-GAAP financial measures are unlikely to be
comparable with non-GAAP information provided by other companies.
The determination of the amounts that are excluded from non-GAAP
financial measures is a matter of management judgment and depends
upon, among other factors, the nature of the underlying expense or
income amounts. Reconciliations between these non-GAAP financial
measures and the most comparable GAAP financial measures are
included in the tables accompanying this press release after the
unaudited condensed consolidated financial statements.
ABOUT AMAGAMAG is a pharmaceutical company
focused on bringing innovative products to patients with unmet
medical needs. The company does this by leveraging its development
and commercial expertise to invest in and grow its pharmaceutical
products across a range of therapeutic areas. For additional
company information, please visit www.amagpharma.com.
FORWARD-LOOKING STATEMENTSThis press release
contains forward-looking information about AMAG Pharmaceuticals,
Inc. within the meaning of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Any statements
contained herein which do not describe historical facts, including,
among others, statements regarding AMAG’s planned divestiture of
Intrarosa and Vyleesi, expected results of and benefits from the
workforce reduction, beliefs that AMAG can maximize Feraheme’s
value or retain patient access to Makena, expectations regarding
the impact of the COVID-19 pandemic on AMAG’s business, including
signs of stabilization, beliefs about the demand for AMAG’s
products, plans to reduce total operating expenses by more than
$100 million in 2020 and the belief that AMAG is on track to
achieve that goal, beliefs that AMAG can undertake efforts to
achieve profitability for 2020, beliefs that AMAG is now the right
size to support long-term goals, statements related to the COVID-19
pandemic and its general impact, potential severity, duration and
spread, beliefs that AMAG’s risk mitigation plans will minimize
potential supply interruptions due to the COVID-19 pandemic,
beliefs that AMAG will be able to work collaboratively with the FDA
to enable continued patient access to Makena, plans to work with
the FDA to initiate the ciraparantag Phase 2b trial and estimates
for Feraheme’s market share are based on management’s current
expectations and beliefs and are forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include, among others, risks and
uncertainties related to the scale and scope of the COVID-19
pandemic and its impact on AMAG’s revenues and operations,
including clinical trials, as well as COVID-19’s impact on AMAG’s
business partners, healthcare providers, patients, employees and
the health care industry and worldwide economies generally, risks
related to efforts to streamline the business, including the
workforce reduction and the planned divestiture of Intrarosa and
Vyleesi, including any unintended consequences from such efforts
and AMAG’s ability to successfully achieve the expected benefits of
such initiatives in a timely manner, or at all, as well as those
risks identified in AMAG’s filings with the U.S. Securities and
Exchange Commission (SEC), including its Annual Report on Form 10-K
for the year ended December 31, 2019, its Current Reports on Form
8-K, its Quarterly Reports on Form 10-Q, including for the quarter
ended March 31, 2020, and in any subsequent filings with the SEC ,
which are available at the SEC’s website at www.sec.gov. Any such
risks and uncertainties could materially and adversely affect
AMAG’s results of operations, its profitability and its cash flows,
which would, in turn, have a significant and adverse impact on
AMAG’s stock price. AMAG cautions you not to place undue reliance
on any forward-looking statements, which speak only as of the date
they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals®, the logo and designs, Feraheme® and
Vyleesi® are registered trademarks of AMAG Pharmaceuticals,
Inc. Makena® is a registered trademark of AMAG Pharma USA,
Inc. Intrarosa® is a registered trademark of Endoceutics,
Inc. Any other trademarks referred to in this report are the
property of their respective owners.
- Tables Follow -
AMAG Pharmaceuticals,
Inc.Condensed Consolidated Statements of
Operations(Unaudited, amounts in thousands, except
for per share data)
|
Three Months Ended March 31, |
|
2020 |
|
2019 |
Revenues: |
|
|
|
Feraheme |
$ |
44,433 |
|
|
$ |
40,015 |
|
Makena |
21,777 |
|
|
31,257 |
|
Intrarosa |
3,169 |
|
|
4,414 |
|
Other |
(751 |
) |
|
43 |
|
Total product revenues |
68,628 |
|
|
75,729 |
|
Other revenues |
33 |
|
|
75 |
|
Total revenues |
68,661 |
|
|
75,804 |
|
Operating costs and
expenses: |
|
|
|
Cost of product sales |
24,359 |
|
|
18,477 |
|
Research and development expenses |
11,180 |
|
|
18,066 |
|
Acquired in-process research and development |
— |
|
|
74,856 |
|
Selling, general and administrative expenses |
52,697 |
|
|
74,682 |
|
Restructuring expenses |
— |
|
|
7,420 |
|
Total costs and expenses |
88,236 |
|
|
193,501 |
|
Operating loss |
(19,575 |
) |
|
(117,697 |
) |
|
|
|
|
Other income (expense): |
|
|
|
Interest expense |
(6,604 |
) |
|
(6,450 |
) |
Interest and dividend income |
477 |
|
|
1,586 |
|
Other income |
1,311 |
|
|
340 |
|
Total other expense, net |
(4,816 |
) |
|
(4,524 |
) |
Loss before income taxes |
(24,391 |
) |
|
(122,221 |
) |
Income tax expense
(benefit) |
100 |
|
|
(137 |
) |
Net loss |
$ |
(24,491 |
) |
|
$ |
(122,084 |
) |
|
|
|
|
Basic and diluted net loss per
share |
$ |
(0.72 |
) |
|
$ |
(3.54 |
) |
|
|
|
|
Weighted average shares
outstanding used to compute net loss per share (basic and
diluted) |
34,104 |
|
|
34,469 |
|
|
|
|
|
|
|
AMAG
Pharmaceuticals, Inc.Condensed Consolidated
Balance Sheets(Unaudited, amounts in
thousands)
|
March 31, 2020 |
|
December 31, 2019 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
54,455 |
|
|
$ |
113,009 |
|
Marketable securities |
70,288 |
|
|
58,742 |
|
Accounts receivable, net |
106,484 |
|
|
94,163 |
|
Inventories |
33,676 |
|
|
31,553 |
|
Prepaid and other current assets |
25,734 |
|
|
19,100 |
|
Total current assets |
290,637 |
|
|
316,567 |
|
Property and equipment,
net |
3,312 |
|
|
4,116 |
|
Goodwill |
422,513 |
|
|
422,513 |
|
Intangible assets, net |
13,783 |
|
|
23,620 |
|
Operating lease right-of-use
asset |
22,835 |
|
|
23,286 |
|
Deferred tax assets |
— |
|
|
630 |
|
Restricted cash |
495 |
|
|
495 |
|
Total assets |
$ |
753,575 |
|
|
$ |
791,227 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
16,520 |
|
|
$ |
27,021 |
|
Accrued expenses |
167,661 |
|
|
177,079 |
|
Current portion of operating lease liability |
4,065 |
|
|
4,077 |
|
Current portion of acquisition-related contingent
consideration |
— |
|
|
17 |
|
Total current liabilities |
188,246 |
|
|
208,194 |
|
Long-term liabilities: |
|
|
|
Convertible notes, net |
281,038 |
|
|
277,034 |
|
Long-term operating lease liability |
19,433 |
|
|
19,791 |
|
Other long-term liabilities |
1,120 |
|
|
89 |
|
Total liabilities |
489,837 |
|
|
505,108 |
|
Commitments and
contingencies |
|
|
|
Stockholders’ equity: |
|
|
|
Preferred stock, par value $0.01 per share, 2,000,000 shares
authorized; none issued |
— |
|
|
— |
|
Common stock, par value $0.01 per share, 117,500,000 shares
authorized; 34,266,256 and 33,999,081 shares issued and outstanding
at March 31, 2020 and December 31, 2019, respectively |
342 |
|
|
339 |
|
Additional paid-in capital |
1,300,572 |
|
|
1,297,917 |
|
Accumulated other comprehensive loss |
(3,787 |
) |
|
(3,239 |
) |
Accumulated deficit |
(1,033,389 |
) |
|
(1,008,898 |
) |
Total stockholders’ equity |
263,738 |
|
|
286,119 |
|
Total liabilities and stockholders’ equity |
$ |
753,575 |
|
|
$ |
791,227 |
|
|
AMAG
Pharmaceuticals, Inc.Condensed Consolidated
Statements of Cash Flows(Unaudited, amounts in
thousands)
|
Three Months Ended March 31, |
|
2020 |
|
2019 |
Cash flows from operating
activities: |
|
|
|
Net loss |
$ |
(24,491 |
) |
|
$ |
(122,084 |
) |
Adjustments to reconcile net
loss to net cash (used in) provided by operating activities: |
|
|
|
Depreciation and amortization |
10,318 |
|
|
4,375 |
|
Provision for bad debt expense |
223 |
|
|
(16 |
) |
Amortization of premium/discount on purchased securities |
4 |
|
|
(27 |
) |
Write-down of inventory |
616 |
|
|
— |
|
Non-cash equity-based compensation expense |
3,868 |
|
|
4,873 |
|
Non-cash IPR&D expense |
— |
|
|
18,029 |
|
Amortization of debt discount and debt issuance costs |
4,004 |
|
|
3,783 |
|
Gains on marketable securities, net |
(9 |
) |
|
— |
|
Change in fair value of contingent consideration |
— |
|
|
(6 |
) |
Deferred income taxes |
630 |
|
|
458 |
|
Non-cash lease expense |
451 |
|
|
— |
|
Gain on sale of assets |
(1,409 |
) |
|
— |
|
Changes in operating assets
and liabilities: |
|
|
|
Accounts receivable, net |
(12,547 |
) |
|
(7,971 |
) |
Inventories |
(2,770 |
) |
|
(2,973 |
) |
Prepaid and other current assets |
(6,490 |
) |
|
(21,580 |
) |
Accounts payable and accrued expenses |
(19,671 |
) |
|
31,432 |
|
Other assets and liabilities |
664 |
|
|
1,799 |
|
Net cash used in operating activities |
(46,609 |
) |
|
(89,908 |
) |
Cash flows from investing
activities: |
|
|
|
Proceeds from sales or maturities of marketable securities |
11,255 |
|
|
27,945 |
|
Purchase of marketable securities |
(23,345 |
) |
|
(14,815 |
) |
Net proceeds from the sale of assets |
1,440 |
|
|
— |
|
Capital expenditures |
(68 |
) |
|
(1,794 |
) |
Net cash (used in) provided by investing activities |
(10,718 |
) |
|
11,336 |
|
Cash flows from financing
activities: |
|
|
|
Payments to settle convertible notes |
— |
|
|
(21,417 |
) |
Payments of contingent consideration |
(17 |
) |
|
(17 |
) |
Payments for repurchases of common stock |
— |
|
|
(13,730 |
) |
Proceeds from the exercise of common stock options |
— |
|
|
33 |
|
Payments of employee tax withholding related to equity-based
compensation |
(1,210 |
) |
|
(1,636 |
) |
Net cash used in financing activities |
(1,227 |
) |
|
(36,767 |
) |
Net decrease in cash,
cash equivalents, and restricted cash |
(58,554 |
) |
|
(115,339 |
) |
Cash, cash equivalents, and
restricted cash at beginning of the period |
113,504 |
|
|
253,751 |
|
Cash, cash equivalents, and
restricted cash at end of the period |
$ |
54,950 |
|
|
$ |
138,412 |
|
Supplemental data for cash
flow information: |
|
|
|
Cash (refunded) paid for taxes |
$ |
(256 |
) |
|
$ |
78 |
|
Cash paid for interest |
$ |
— |
|
|
$ |
267 |
|
Non-cash investing and
financing activities: |
|
|
|
Settlement of note receivable in connection with Perosphere
acquisition |
$ |
— |
|
|
$ |
10,000 |
|
Right-of-use assets obtained in exchange for lease liabilities |
$ |
— |
|
|
$ |
918 |
|
|
|
|
|
|
|
|
|
AMAG
Pharmaceuticals, Inc.Reconciliation of
Condensed Consolidated Statements of Operations to Non-GAAP
Statements of OperationsThree Months Ended March
31, 2020 (Unaudited, amounts in
thousands)
|
Revenue |
|
Cost of product sales |
|
Research & development |
|
Selling, general & administrative |
|
Operating Loss / Adjusted EBITDA |
GAAP |
$ |
68,661 |
|
|
$ |
24,359 |
|
|
$ |
11,180 |
|
|
$ |
52,697 |
|
|
$ |
(19,575 |
) |
Depreciation and intangible
asset amortization |
— |
|
|
(9,837 |
) |
|
(76 |
) |
|
(405 |
) |
|
|
Stock-based compensation |
— |
|
|
(203 |
) |
|
(70 |
) |
|
(3,512 |
) |
|
|
Non-GAAP
Adjusted |
$ |
68,661 |
|
|
$ |
14,319 |
|
|
$ |
11,034 |
|
|
$ |
48,780 |
|
|
$ |
(5,472 |
) |
|
AMAG
Pharmaceuticals, Inc.Reconciliation of
Condensed Consolidated Statements of Operations to Non-GAAP
Statements of OperationsThree Months Ended March
31, 2019 (Unaudited, amounts in
thousands)
|
Revenue |
|
Cost of product sales |
|
Research & development |
|
Selling, general & administrative |
|
Acquired IPR&D |
|
Restructuring |
|
Operating Loss / Adjusted EBITDA |
GAAP |
$ |
75,804 |
|
|
$ |
18,477 |
|
|
$ |
18,066 |
|
|
$ |
74,682 |
|
|
$ |
74,856 |
|
|
$ |
7,420 |
|
|
$ |
(117,697 |
) |
Depreciation and intangible
asset amortization |
— |
|
|
(3,943 |
) |
|
(8 |
) |
|
(424 |
) |
|
— |
|
|
— |
|
|
|
Stock-based compensation |
— |
|
|
(202 |
) |
|
(680 |
) |
|
(3,325 |
) |
|
— |
|
|
— |
|
|
|
Acquisition-related costs |
— |
|
|
— |
|
|
— |
|
|
(270 |
) |
|
— |
|
|
— |
|
|
|
Restructuring |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(7,420 |
) |
|
|
Acquired IPR&D |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(74,856 |
) |
|
— |
|
|
|
Non-GAAP
Adjusted |
$ |
75,804 |
|
|
$ |
14,332 |
|
|
$ |
17,378 |
|
|
$ |
70,663 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(26,569 |
) |
|
AMAG
Pharmaceuticals, Inc.Share Count
Reconciliation(Unaudited, amounts in
millions)
|
|
Three Months Ended March 31, |
|
|
|
2020 |
|
2019 |
|
Weighted avg. basic
and diluted shares outstanding |
|
34.1 |
|
34.5 |
|
Employee equity incentive awards |
|
0.2 |
2 |
0.2 |
3 |
Non-GAAP diluted
shares outstanding |
|
34.3 |
|
34.7 |
|
|
2 Employee equity incentive awards would be anti-dilutive in
this period.3 Reflects the non-GAAP dilutive impact of employee
equity incentive awards.
CONTACT:Linda Lennox908-627-3424
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Apr 2023 bis Apr 2024